Business
Rule 17 Disclosure
Rule 17 Disclosure.
About this update from Theracryf Plc
[{"type":"text","content":"\n\n \nEvgen Pharma plc\n(\"Evgen\" or \"the Company\" or \"the Group\")\n \nRule 17 Disclosure\n \nAlderley Park, UK - 3 August 2023: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines, notes that private UK-based cell and gene therapy company Ixaka Ltd has entered administration. Evgen's CEO, Huw Jones, is a non-executive director of Ixaka Ltd.\n \nThere are no further disclosures required pursuant to AIM Rule 17.\n \n-Ends-\n\n \nEnquiries:\n \n\n\n\n\n\nEvgen Pharma PLC\nDr Huw Jones, CEO \nDr Helen Kuhlman, CBO\n\n\n\n+44 1625 466591\n\n\n\n\nFinnCap (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance)\nNigel Birks / Harriet Ward (ECM)\n\n\n\n+44 20 7220 0500\n\n\n\n\nInstinctif Partners\nMelanie Toyne-Sewell / Rozi Morris/ Adam Loudon\n\n+44 207 457 2020 [email protected]\n\n\n\n\n\n \n\nNotes to Editors\n \nAbout Evgen Pharma plc \n \nEvgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane. \n \nThe Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.\n \nThe Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.\n \nThe Company has its headquarters and registered office at...